Bill

Bill > HR4866


US HR4866

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020


summary

Introduced
10/28/2019
In Committee
07/15/2020
Crossed Over
09/22/2020
Passed
Dead
12/31/2020

Introduced Session

116th Congress

Bill Summary

AN ACT To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

AI Summary

This bill amends the 21st Century Cures Act to establish National Centers of Excellence in Continuous Pharmaceutical Manufacturing. The bill directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to designate institutions of higher education that meet certain criteria as National Centers of Excellence to support the advancement and development of continuous manufacturing. The bill provides funding for the designated centers to study and recommend improvements to continuous manufacturing, and requires the Secretary to report annually to Congress on the centers' activities and findings. The bill also requires the Secretary to develop a report on the FDA's long-term vision for supporting continuous manufacturing in pharmaceutical development and regulation.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (3)

Last Action

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 09/22/2020)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...